{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:30:01Z","timestamp":1793320201221,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001030","name":"National Heart Foundation of Australia","doi-asserted-by":"publisher","award":["101656"],"award-info":[{"award-number":["101656"]}],"id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1160379"],"award-info":[{"award-number":["APP1160379"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Snow Foundation"},{"DOI":"10.13039\/501100017001","name":"Li Ka Shing Institute of Virology, University of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004148","name":"Lowitja Institute","doi-asserted-by":"publisher","award":["CRCATSIH CF 001"],"award-info":[{"award-number":["CRCATSIH CF 001"]}],"id":[{"id":"10.13039\/501100004148","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Australian Tropical Medicine and Commercialisation","award":["ATMC50301"],"award-info":[{"award-number":["ATMC50301"]}]},{"DOI":"10.13039\/100008436","name":"National Foundation for Medical Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We have developed two candidate vaccines to protect against multiple strains of Strep A infections. The candidates are combinatorial synthetic peptide vaccines composed of a M protein epitope (J8 or p*17) and a non-M protein epitope (K4S2). To enhance immunogenicity, each peptide is conjugated to the carrier protein CRM<jats:sub>197<\/jats:sub> (CRM) and formulated with aluminium hydroxide adjuvant Alhydrogel (Alum) to make the final vaccines, J8-CRM\u2009+\u2009K4S2-CRM\/Alum and p*17-CRM\u2009+\u2009K4S2-CRM\/Alum. The safety and toxicity of each vaccine was assessed. Sprague Dawley rats were administered three intramuscular doses, over a six-week study with a 4-week recovery period. A control group received CRM only formulated with Alum (CRM\/Alum). There was no evidence of systemic toxicity in the rats administered either vaccine. There was an associated increase in white blood cell, lymphocyte and monocyte counts, increased adrenal gland weights, adrenocortical hypertrophy, and increased severity of granulomatous inflammation at the sites of injection and the associated inguinal lymph nodes. These changes were considered non-adverse. All rats administered vaccine developed a robust and sustained immunological response. The absence of clinical toxicity and the development of an immunological response in the rats suggests that the vaccines are safe for use in a phase 1 clinical trial in healthy humans.<\/jats:p>","DOI":"10.1038\/s41598-020-80508-6","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T11:13:01Z","timestamp":1610104381000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines"],"prefix":"10.1038","volume":"11","author":[{"given":"Simone","family":"Reynolds","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainslie","family":"Calcutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Batzloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Ozberk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie-Lee","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Good","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"80508_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jama.292.6.709","volume":"292","author":"KL Kotloff","year":"2004","unstructured":"Kotloff, K. L. et al. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. JAMA 292, 709\u2013715 (2004).","journal-title":"JAMA"},{"key":"80508_CR2","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1086\/444458","volume":"41","author":"SA McNeil","year":"2005","unstructured":"McNeil, S. A. et al. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin. Infect. Dis. 41, 1114\u20131122 (2005).","journal-title":"Clin. Infect. Dis."},{"key":"80508_CR3","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1128\/CDLI.12.7.833-836.2005","volume":"12","author":"JB Dale","year":"2005","unstructured":"Dale, J. B. et al. Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes. Clin. Diagn. Lab. Immunol. 12, 833\u2013836 (2005).","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"80508_CR4","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.vaccine.2019.12.005","volume":"38","author":"E Pastural","year":"2020","unstructured":"Pastural, E. et al. Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: a randomized, controlled phase I study. Vaccine 38, 1384\u20131392. https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.005 (2020).","journal-title":"Vaccine"},{"key":"80508_CR5","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/intimm\/9.11.1723","volume":"9","author":"WA Hayman","year":"1997","unstructured":"Hayman, W. A. et al. Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Int. Immunol. 9, 1723\u20131733 (1997).","journal-title":"Int. Immunol."},{"key":"80508_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1046\/j.1365-2567.1996.d01-754.x","volume":"89","author":"ER Brandt","year":"1996","unstructured":"Brandt, E. R. et al. Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci. Immunology 89, 331\u2013337 (1996).","journal-title":"Immunology"},{"key":"80508_CR7","volume-title":"Streptococcus Pyogenes: Basic Biology to Clinical Manifestations","author":"JB Dale","year":"2016","unstructured":"Dale, J. B. et al. In Streptococcus Pyogenes: Basic Biology to Clinical Manifestations (eds Ferretti, J. J. et al.) (University of Oklahoma Health Sciences Center, Oklahoma City, 2016)."},{"key":"80508_CR8","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00693-19","author":"T Rivera-Hernandez","year":"2019","unstructured":"Rivera-Hernandez, T. et al. An experimental group A streptococcus vaccine that reduces pharyngitis and tonsillitis in a nonhuman primate model. mBio https:\/\/doi.org\/10.1128\/mBio.00693-19 (2019).","journal-title":"mBio"},{"key":"80508_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0417-8","author":"MR Davies","year":"2019","unstructured":"Davies, M. R. et al. Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics. Nat. Genet. https:\/\/doi.org\/10.1038\/s41588-019-0417-8 (2019).","journal-title":"Nat. Genet."},{"key":"80508_CR10","doi-asserted-by":"publisher","first-page":"5915","DOI":"10.4049\/jimmunol.1500157","volume":"194","author":"M Pandey","year":"2015","unstructured":"Pandey, M. et al. A synthetic M protein peptide synergizes with a CXC chemokine protease to induce vaccine-mediated protection against virulent streptococcal pyoderma and bacteremia. J. Immunol. 194, 5915\u20135925. https:\/\/doi.org\/10.4049\/jimmunol.1500157 (2015).","journal-title":"J. Immunol."},{"key":"80508_CR11","doi-asserted-by":"publisher","first-page":"4923","DOI":"10.1016\/j.vaccine.2009.06.042","volume":"27","author":"CE Turner","year":"2009","unstructured":"Turner, C. E., Kurupati, P., Wiles, S., Edwards, R. J. & Sriskandan, S. Impact of immunization against SpyCEP during invasive disease with two streptococcal species: streptococcus pyogenes and Streptococcus equi. Vaccine 27, 4923\u20134929. https:\/\/doi.org\/10.1016\/j.vaccine.2009.06.042 (2009).","journal-title":"Vaccine"},{"key":"80508_CR12","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1086\/374800","volume":"187","author":"MR Batzloff","year":"2003","unstructured":"Batzloff, M. R. et al. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. J. Infect. Dis. 187, 1598\u20131608 (2003).","journal-title":"J. Infect. Dis."},{"key":"80508_CR13","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1080\/21645515.2016.1222999","volume":"12","author":"MR Batzloff","year":"2016","unstructured":"Batzloff, M. R. et al. Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate. Hum. Vaccines Immunother. 12, 3089\u20133096. https:\/\/doi.org\/10.1080\/21645515.2016.1222999 (2016).","journal-title":"Hum. Vaccines Immunother."},{"key":"80508_CR14","doi-asserted-by":"publisher","first-page":"e0198658","DOI":"10.1371\/journal.pone.0198658","volume":"13","author":"S Sekuloski","year":"2018","unstructured":"Sekuloski, S. et al. Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial. PLoS ONE 13, e0198658. https:\/\/doi.org\/10.1371\/journal.pone.0198658 (2018).","journal-title":"PLoS ONE"},{"key":"80508_CR15","first-page":"12","volume":"9","author":"WA Relf","year":"1996","unstructured":"Relf, W. A. et al. Mapping a conserved conformational epitope from the M protein of group A streptococci. Pept. Res. 9, 12\u201320 (1996).","journal-title":"Pept. Res."},{"key":"80508_CR16","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.4049\/jimmunol.1700836","volume":"199","author":"T Nordstrom","year":"2017","unstructured":"Nordstrom, T. et al. Enhancing vaccine efficacy by engineering a complex synthetic peptide to become a super immunogen. J. Immunol. 199, 2794\u20132802. https:\/\/doi.org\/10.4049\/jimmunol.1700836 (2017).","journal-title":"J. Immunol."},{"key":"80508_CR17","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.4049\/jimmunol.1501994","volume":"196","author":"M Pandey","year":"2016","unstructured":"Pandey, M. et al. Combinatorial synthetic peptide vaccine strategy protects against hypervirulent CovR\/S mutant streptococci. J. Immunol. 196, 3364\u20133374. https:\/\/doi.org\/10.4049\/jimmunol.1501994 (2016).","journal-title":"J. Immunol."},{"key":"80508_CR18","doi-asserted-by":"publisher","first-page":"13786","DOI":"10.1038\/s41598-017-14157-7","volume":"7","author":"M Pandey","year":"2017","unstructured":"Pandey, M. et al. Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase I trial. Sci. Rep. 7, 13786. https:\/\/doi.org\/10.1038\/s41598-017-14157-7 (2017).","journal-title":"Sci. Rep."},{"key":"80508_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41541-018-0053-9","volume":"3","author":"M Pandey","year":"2018","unstructured":"Pandey, M. et al. Skin infection boosts memory B-cells specific for a cryptic vaccine epitope of group A streptococcus and broadens the immune response to enhance vaccine efficacy. NPJ Vaccines 3, 15. https:\/\/doi.org\/10.1038\/s41541-018-0053-9 (2018).","journal-title":"NPJ Vaccines"},{"key":"80508_CR20","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1177\/0192623312466452","volume":"41","author":"NE Everds","year":"2013","unstructured":"Everds, N. E. et al. Interpreting stress responses during routine toxicity studies: a review of the biology, impact, and assessment. Toxicol. Pathol. 41, 560\u2013614. https:\/\/doi.org\/10.1177\/0192623312466452 (2013).","journal-title":"Toxicol. Pathol."},{"key":"80508_CR21","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1177\/0192623313478692","volume":"41","author":"F Chanut","year":"2013","unstructured":"Chanut, F. et al. Spontaneous cardiomyopathy in young Sprague\u2013Dawley rats: evaluation of biological and environmental variability. Toxicol. Pathol. 41, 1126\u20131136. https:\/\/doi.org\/10.1177\/0192623313478692 (2013).","journal-title":"Toxicol. Pathol."},{"key":"80508_CR22","volume-title":"Streptococcus pyogenes: Basic Biology to Clinical Manifestations","author":"D Sika-Paotonu","year":"2016","unstructured":"Sika-Paotonu, D., Beaton, A., Raghu, A., Steer, A. & Carapetis, J. In Streptococcus pyogenes: Basic Biology to Clinical Manifestations: Basic Biology to Clinical Manifestations (eds Ferretti, J. J. et al.) (University of Oklahoma, Oklahoma, 2016)."},{"key":"80508_CR23","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1128\/IAI.65.9.3913-3923.1997","volume":"65","author":"MW Cunningham","year":"1997","unstructured":"Cunningham, M. W., Antone, S. M., Smart, M., Liu, R. & Kosanke, S. Molecular analysis of human cardiac myosin-cross-reactive B- and T-cell epitopes of the group A streptococcal M5 protein. Infect. Immun. 65, 3913\u20133923 (1997).","journal-title":"Infect. Immun."},{"key":"80508_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/s0896-8411(03)00026-x","volume":"20","author":"RS Lymbury","year":"2003","unstructured":"Lymbury, R. S. et al. Induction of autoimmune valvulitis in Lewis rats following immunization with peptides from the conserved region of group A streptococcal M protein. J. Autoimmun. 20, 211\u2013217. https:\/\/doi.org\/10.1016\/s0896-8411(03)00026-x (2003).","journal-title":"J. Autoimmun."},{"key":"80508_CR25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s12265-013-9526-4","volume":"7","author":"CA Kirvan","year":"2014","unstructured":"Kirvan, C. A., Galvin, J. E., Hilt, S., Kosanke, S. & Cunningham, M. W. Identification of streptococcal m-protein cardiopathogenic epitopes in experimental autoimmune valvulitis. J. Cardiovasc. Transl. Res. 7, 172\u2013181. https:\/\/doi.org\/10.1007\/s12265-013-9526-4 (2014).","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"80508_CR26","doi-asserted-by":"publisher","first-page":"e0156639","DOI":"10.1371\/journal.pone.0156639","volume":"11","author":"C McNeilly","year":"2016","unstructured":"McNeilly, C. et al. Predicted coverage and immuno-safety of a recombinant C-repeat region based streptococcus pyogenes vaccine candidate. PLoS ONE 11, e0156639. https:\/\/doi.org\/10.1371\/journal.pone.0156639 (2016).","journal-title":"PLoS ONE"},{"key":"80508_CR27","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1093\/nar\/25.17.3389","volume":"25","author":"SF Altschul","year":"1997","unstructured":"Altschul, S. F. et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucl. Acids Res. 25, 3389\u20133402. https:\/\/doi.org\/10.1093\/nar\/25.17.3389 (1997).","journal-title":"Nucl. Acids Res."},{"key":"80508_CR28","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1016\/j.vaccine.2007.01.079","volume":"25","author":"MS Shaila","year":"2007","unstructured":"Shaila, M. S. et al. Comparative in silico analysis of two vaccine candidates for group A streptococcus predicts that they both may have similar safety profiles. Vaccine 25, 3567\u20133573 (2007).","journal-title":"Vaccine"},{"key":"80508_CR29","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1021\/bi992256r","volume":"39","author":"SW Kim","year":"2000","unstructured":"Kim, S. W. et al. Identification of functionally important amino acid residues within the C2-domain of human factor V using alanine-scanning mutagenesis. Biochemistry 39, 1951\u20131958. https:\/\/doi.org\/10.1021\/bi992256r (2000).","journal-title":"Biochemistry"},{"key":"80508_CR30","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1046\/j.1538-7836.2003.00143.x","volume":"1","author":"E Ajzner","year":"2003","unstructured":"Ajzner, E. et al. Anti-factor V auto-antibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding. J. Thromb. Haemost. 1, 943\u2013949. https:\/\/doi.org\/10.1046\/j.1538-7836.2003.00143.x (2003).","journal-title":"J. Thromb. Haemost."},{"key":"80508_CR31","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1055\/s-0037-1615962","volume":"85","author":"T Izumi","year":"2001","unstructured":"Izumi, T. et al. Fine mapping of inhibitory anti-factor V antibodies using factor V C2 domain mutants. Identification of two antigenic epitopes involved in phospholipid binding. Thromb. Haemost. 85, 1048\u20131054 (2001).","journal-title":"Thromb. Haemost."},{"key":"80508_CR32","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.4049\/jimmunol.1202333","volume":"190","author":"M Pandey","year":"2013","unstructured":"Pandey, M., Wykes, M. N., Hartas, J., Good, M. F. & Batzloff, M. R. Long-term antibody memory induced by synthetic peptide vaccination is protective against Streptococcus pyogenes infection and is independent of memory T cell help. J. Immunol. 190, 2692\u20132701. https:\/\/doi.org\/10.4049\/jimmunol.1202333 (2013).","journal-title":"J. Immunol."},{"key":"80508_CR33","volume-title":"Appraisal of the Safety of Chemicals in Foods, Drugs, and Cosmetics","author":"U.S. Food and Drug Administration","year":"1959","unstructured":"U.S. Food and Drug Administration. Appraisal of the Safety of Chemicals in Foods, Drugs, and Cosmetics (Association of Food & Drug Officials of the United States, Galveston, 1959)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80508-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80508-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80508-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:55:31Z","timestamp":1670028931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80508-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["80508"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-80508-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]},"assertion":[{"value":"14 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"127"}}